

# British Journal of Pain

<http://bjp.sagepub.com/>

---

## Establishing the characteristics for patients with chronic Complex Regional Pain Syndrome: the value of the CRPS-UK Registry

Nicholas Shenker, Andreas Goebel, Mark Rockett, James Batchelor, Gareth T Jones, Richard Parker, Amanda C de C Williams and Candida McCabe

*British Journal of Pain* published online 9 July 2014

DOI: 10.1177/2049463714541423

The online version of this article can be found at:

<http://bjp.sagepub.com/content/early/2014/07/03/2049463714541423>

---

Published by:



<http://www.sagepublications.com>

On behalf of:



THE BRITISH PAIN SOCIETY

[British Pain Society](#)

Additional services and information for *British Journal of Pain* can be found at:

**Email Alerts:** <http://bjp.sagepub.com/cgi/alerts>

**Subscriptions:** <http://bjp.sagepub.com/subscriptions>

**Reprints:** <http://www.sagepub.com/journalsReprints.nav>

**Permissions:** <http://www.sagepub.com/journalsPermissions.nav>

>> [OnlineFirst Version of Record](#) - Jul 9, 2014

[What is This?](#)



# Establishing the characteristics for patients with chronic Complex Regional Pain Syndrome: the value of the CRPS-UK Registry

British Journal of Pain

1-8

© The British Pain Society 2014

Reprints and permissions:

sagepub.co.uk/

journalsPermissions.nav

DOI: 10.1177/2049463714541423

bjp.sagepub.com



Nicholas Shenker<sup>1</sup>, Andreas Goebel<sup>2</sup>, Mark Rockett<sup>3</sup>, James Batchelor<sup>4</sup>, Gareth T Jones<sup>5</sup>, Richard Parker<sup>6</sup>, Amanda C de C Williams<sup>7</sup> and Candida McCabe<sup>8</sup>

## Abstract

**Objective:** The long-term prognosis of patients with Complex Regional Pain Syndrome (CRPS) is unknown with no reported prospective studies from the United Kingdom longer than 18 months. The CRPS-UK Network aims to study this by use of a Registry. The aims of this article are, to outline the CRPS-UK Registry, assess the validity of the data and to describe the characteristics of a sample of the UK CRPS population.

**Methods:** A web-based CRPS-UK Registry was developed and made accessible to centres experienced in diagnosing and managing patients with CRPS. Pragmatic annual follow-up questions were agreed.

**Results:** Up until July 2013, the Registry has recruited 240 patients. A blinded, validation study of 20 consecutive patients from two centres (10 each) demonstrated 95.6% completion and 99.4% accuracy of a random sample of the recorded data. These patients had chronic disease (median duration: 29 months); 72.5% were female (2.6:1), with a mean age at symptoms onset of 43 years, and were left-handed more than expected (21.8% versus 10% in the general population). Patients reported a delayed diagnosis, with the median time between symptom onset and diagnosis of 6 months. In all, 30 patients (12.5%) had multiple limb involvement and (83.3%) had a contiguous spread of CRPS.

**Conclusion:** CRPS-UK Registry is a validated method for actively recruiting well-characterised patients with CRPS to provide further information on the long-term outcome.

## Keywords

Complex regional pain syndromes, chronic pain, causalgia, pain, intractable, reflex sympathetic dystrophy

## Key points

- Patients with Complex Regional Pain Syndrome can be recruited to the CRPS-UK Registry
- CRPS that lasts for more than one year continues with pain and associated signs
- Chronic CRPS appears to occur more frequently in left-handed individuals

<sup>1</sup>Rheumatology Research Unit, Department of Rheumatology, Cambridge University Hospitals, Cambridge, UK

<sup>2</sup>Department of Pain Medicine, Walton Centre, Liverpool, UK

<sup>3</sup>Department of Anaesthetics, Derriford Hospital, Plymouth, UK

<sup>4</sup>Department of ICT, University of Southampton, Southampton, UK

<sup>5</sup>Epidemiology Group, Institute for Applied Health Sciences, University of Aberdeen, Aberdeen, UK

<sup>6</sup>Department of Primary Care Research, University of Cambridge, Cambridge, UK

<sup>7</sup>Department of Clinical, Educational & Health Psychology, University College London, London, UK

<sup>8</sup>Centre for Health and Clinical Research, University of the West of England, Bristol, UK

## Corresponding author:

Nicholas Shenker, Rheumatology Research Unit, Department of Rheumatology, Cambridge University Hospitals, Box 204, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.  
Email: nicholas.shenker@addenbrookes.nhs.uk

**Table 1.** Comparative data of two community-based studies of CRPS.

	De Mos et al. <sup>2</sup>	Sandroni et al. <sup>3</sup>
Geography	The Netherlands	Rochester, USA
Time period	1996–2005	1990
Population sample (n)	190,902	106,470
Cases (n)	238	74
Incidence	26/100,000	6/100,000
Peak age of incidence (years)	61–70	51–60
Prevalence	–	21/100,000
<b>CRPS demographics</b>		
Average age (years)	52.7	46.9
Female (%)	77.3	81.1
CRPS type II (%)	2.9	12.9
Trigger (%):	44	46
Fracture	23.1	12
Soft tissue	18.1	–
Post-operation	8.8	42
Other	1.3	0
Spontaneous/unknown		
Arm:leg ratio	1.5:1	2:1
Multiple sites (%)	–	4.1

## Introduction

Complex Regional Pain Syndrome (CRPS) is a disabling, usually post-traumatic condition, characterised by severe pain and changes in the appearance of a limb (see Diagnostic Criteria).<sup>1</sup> Community studies have demonstrated an incidence of CRPS of between 5 (United States) and 20 (The Netherlands) per 100,000 population, with 70–80% having resolution of their symptoms within 1 year.<sup>2,3</sup> Sandroni estimated the prevalence to be ~ 20 per 100,000 (Table 1). From these two studies, ~ 25% of patients will have unrelenting pain for more than 1 year after the onset of symptoms with effects on employment, quality of life, activities of daily living and mood. In the United Kingdom, therefore, at least 10,000 adults have experienced CRPS for longer than 1 year. What is their prognosis?

Three prospective studies have examined long-term outcomes of patients with CRPS. Vaneker et al.<sup>4</sup> followed 45 patients with upper limb CRPS diagnosed using the Veldman criteria for 8 years using the validated Impairment Level Sumscore (ISS). Temperature and range of movement scores had improved whereas the global ISS had no significant change. In the randomised controlled trial by Kemler et al.,<sup>5</sup> 64 patients with CRPS reported pain scores of 4–6 out of 10, 5 years after recruitment. Zyluk published a single-centre follow-up of 27 out of 30 patients with reflex sympathetic dystrophy in Poland followed for 13 months on average. Pain and swelling resolved but some patients were still functionally weak. At least four

retrospective reviews have noted the outcomes of patients with CRPS.<sup>6</sup> Geertzen et al.<sup>7</sup> studied 65 patients finding that 62% of patients were still limited in their activities of daily living 5 years after diagnosis. Galer et al.<sup>8</sup> surveyed 31 patients with a mean duration of symptoms of 3.3 years. Pain levels ranged between 3.9 and 7.3 out of 10 with an average of 5.9. Field et al.<sup>9</sup> published a cohort of 100 Colles fracture patients with 55 having had a follow-up at 10 years. Six patients were identified to have finger stiffness 12 weeks after fracture. All six continued to have evidence of CRPS (algodystrophy) at 10 years. Finally, De Mos et al.<sup>10</sup> identified 102 CRPS patients from the Dutch general practitioners database who had had symptoms for an average of 5.8 years. In all, 16% reported the CRPS as still progressive and 31% were incapable of working.

Taken together, these studies suggest a poor outcome for patients with CRPS existing more than 1 year. Poor follow-up, small numbers and inexact diagnostic criteria undermine these results. Research and diagnostic criteria have recently been published allowing more uniformity of study patients and thus comparison across datasets.<sup>1</sup> Patients' prognoses may have improved as newer therapies including innovative rehabilitation strategies and pharmacotherapies become available. Furthermore, increased clinician awareness following the publication of the CRPS-UK Guidelines and earlier intervention may have improved the long-term outcome for patients with CRPS.<sup>11</sup> A larger and more contemporary study is needed.

No prospective studies in United Kingdom have followed patients with CRPS for more than 1 year after

**Table 2.** Diagnostic criteria for CRPS.<sup>1</sup>

A history of symptoms or the presence of signs are assessed the following categories:

<i>Sensory</i>	Hypersensitivity to sensations such as light touch; temperature; deep pressure or pinprick. Allodynia or hyperalgesia.
<i>Vasomotor</i>	Temperature asymmetry; skin colour changes; skin colour asymmetry
<i>Sudomotor</i>	Oedema; sweating changes; sweating asymmetry
<i>Motor/trophic</i>	Decreased range of motion; motor dysfunction (weakness, tremor, dystonia); trophic changes (hair, nail, skin)

Diagnostic criteria for CRPS are met when symptoms in 3 domains are reported and signs in two domains are witnessed. Research criteria are met when symptoms in four domains are reported in the presence of signs in at least two domains.

symptom onset despite the condition being significantly associated with a poor quality of life.<sup>11</sup> In 2008, the CRPS-UK Network, a group of rheumatologists, anaesthetists, allied health professionals and researchers interested in this condition, established the CRPS-UK Registry. This 35-year project will complement other international Registries, provide prognostic information for a cohort of patients diagnosed with CRPS in the United Kingdom in the 21st century and provide a resource for further studying this condition. The aims of this article are to outline the CRPS-UK Registry, assess the validity of the data and to describe the characteristics of a sample of the UK CRPS population.

## Methods

The CRPS-UK Registry is based on EDGE, a Secure Socket Layer encrypted web-based research management resource developed by the Cancer Research UK Clinical Centre, Clinical Informatics Research Unit, University of Southampton. Patients are fully consented to provide personal contact details to be uploaded to the Registry by a clinician (N.S., M.R., A.G., C.M.), who has confirmed the clinical diagnosis. The CRPS-UK Registry is fully approved by National Research Ethics Service (NRES) (REC No: 08/H0306/38) and sponsored by Cambridge University Hospitals' National Health Services (NHS) Foundation Trust.

The diagnosis is confirmed by the application of the International Association for the Study of Pain (IASP, Budapest) diagnostic criteria<sup>1</sup> by a clinician experienced in the diagnosis and management of patients with CRPS (see Table 2).

The database collected 37 variables (detailed in Appendix 1) and was uploaded by the recruiting physician or research nurse. Patients with CRPS, either type 1 (no major nerve damage) or type 2 (major nerve damage), are recruited. Children under the age of 18 years require the consent of the responsible guardian or parent. It is recorded, whether the patient meets diagnostic or research criteria on the Budapest definitions. This recruitment strategy ensures a reliably

homogeneous study population, although it does not reflect the entirety of the population who develop CRPS. Patients with self-limiting CRPS or non-specific limb pain in the absence of vasomotor, trophic, motor and sudomotor changes are likely to be under-represented in this Registry as they will be less likely to be referred to the centres who are actively recruiting.

Up to July 2013, recruitment to the Registry was from four centres throughout the United Kingdom: Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath; Department of Pain Medicine, Walton Centre NHS Foundation Trust, Liverpool; Department of Rheumatology, Addenbrooke's Hospital, Cambridge; and Pain Clinic, Department of Anaesthetics, Derriford Hospital, Plymouth. All centres have local R&D committee approval to contribute to the Registry.

## Data validation

To determine the validity of the Registry data, a sample of 20 patients (10 each from two centres (N.S., C.M.)) was selected in 2011. This was performed by obtaining the previous 10 records that were available from each of two centres. Accuracy and completeness of all recorded variables were compared with the 'gold standard' of medical case notes. Completeness was defined as the proportion of the data entered and accuracy was defined as the percentage of the total data that correctly matched data from the medical record. In the CRPS-UK Registry, each patient has 37 variables recorded, thus giving a total of 740 data points to be analysed.

## Statistical analysis

Descriptive statistics were calculated for the demographic and baseline data of the cohort. Means, standard deviations and ranges were calculated for the continuous variable age, while medians, interquartile ranges (IQR) and ranges were calculated for the other variables since they exhibited a skewed distribution. Frequencies and percentages were calculated for the categorical variables. A binomial test was used to test against the null

**Table 3.** Demographics and Baseline data of cohort.

	No. of recruited patients (%)
<b>Gender</b> (N = 240)	
Male	66 (27.5)
Female	174 (72.5)
<b>Age at onset of symptoms</b> (years) (N = 239)	Mean 43 years (range 12–78, SD 12.7)
<b>Duration of symptoms at recruitment</b> (months) (N = 237)	Median 29 months (range 0–297, IQR 39.7)
<b>Delay between onset and diagnosis</b> (months) (N = 209)	Median 6 months (range 0–129, IQR 13.4)
<b>Trigger</b> (N = 236)	
Fracture	66 (28.0)
Soft tissue injury	69 (29.2)
Surgery	56 (23.7)
Spontaneous	37 (15.7)
Nerve injury	5 (2.1)
Electric injury	1 (0.4)
Other	2 (0.8)
<b>First limb affected</b> (N = 239)	
Right arm	65 (27.2)
Left arm	50 (20.9)
Right leg	55 (23.0)
Left leg	69 (28.9)
<b>Hand dominance (original)</b> (N = 160)	
Right	133 (83.1)
Left	27 (16.9)
<b>Hand dominance (current)</b> (N = 124)	
Right	97 (78.2)
Left	27 (21.8)
<b>Second area (if any) affected</b> (N = 30)	
Right arm	3 (10.0)
Left arm	6 (20.0)
Right leg	10 (33.3)
Left leg	10 (33.3)
Right eye and neck	1 (3.3)
<b>Time between onset of symptoms in first limb and second area</b> (months) (N = 26)	Median 15 months (range 0–130, IQR 29.5)

hypothesis that the percentage right-handed in the CRPS-UK Registry is the same as that in the general population, and separately to test if the percentage of patients with diagonal collateral spread was significantly different from the percentage expected (33%). A Fisher's exact test was used to investigate any association between hand dominance and the first limb affected with CRPS. Statistical significance was concluded if  $p < 0.05$ .

## Results

In July 2013, 240 patients with CRPS had been recruited. All fulfilled the diagnostic Budapest criteria for CRPS and 58 (24.2%) met the tighter research criteria. The demographic and disease related results are displayed in Table 3, and the patient symptoms and signs at the time of recruitment are displayed in Table 4.

With respect to data validation, the completeness of the database was 95.6%, with an accuracy of 99.4%.

This compares favourably with other published registries.<sup>12,13</sup>

The CRPS-UK Registry is predominantly a female cohort (72.5%, 2.6:1) with the average age of symptom onset at 43 years (SD 12.7), and recruitment into the Registry at 46 years (SD 12.3). Patients had had the symptoms for an average of 29 months (IQR 39.7) before being recruited into the Registry. The median self-reported time from onset of symptoms to diagnosis was 6 months (IQR 13.4).

It is clear that this group of patients have ongoing symptoms despite having more than 2 years of symptoms on average. More than 88% of the patients included in the database reported ongoing allodynia. A reduced range of movement and weakness were also very prevalent in this cohort with more than 89% of all patients reporting these symptoms and more than 83% of the cohort having these documented on examination. Dystonia was reported to be the least common

**Table 4.** Symptoms and signs at recruitment to the CRPS-UK Registry.

	Symptoms (%)				Signs (%)			
	N	Now	Previous	Never	N	Now	Absent	Not tested
<b>Sensory</b>								
Allodynia	232	206 (88.8)	19 (8.2)	7 (3.0)	237	205 (86.5)	28 (11.8)	4 (1.7)
<b>Vasomotor</b>								
Temperature asymmetry	232	204 (87.9)	18 (7.8)	10 (4.3)	238	147 (61.8)	76 (31.9)	15 (6.3)
Skin colour asymmetry	233	204 (87.6)	18 (7.7)	11 (4.7)	239	160 (66.9)	73 (31.6)	6 (2.5)
Oedema	230	172 (74.8)	49 (21.3)	9 (3.9)	234	137 (58.5)	93 (39.8)	4 (1.7)
Sweating asymmetry	232	118 (50.9)	55 (23.7)	59 (25.4)	236	88 (37.3)	130 (55.1)	18 (7.6)
<b>Motor</b>								
Reduced ROM	230	206 (89.5)	16 (7.0)	8 (3.5)	239	208 (87.0)	27 (11.3)	4 (1.7)
Weakness	228	205 (89.9)	13 (5.7)	10 (4.4)	238	198 (83.2)	29 (12.2)	11 (4.6)
Tremor	229	83 (36.3)	57 (24.9)	89 (38.8)	237	67 (28.3)	147 (62.0)	23 (9.7)
Dystonia	227	62 (27.3)	57 (25.1)	108 (47.6)	236	60 (25.4)	150 (63.6)	26 (11.0)
<b>Trophic</b>								
Hair changes	231	71 (30.7)	73 (31.6)	87 (37.7)	235	66 (28.1)	148 (63.0)	21 (8.9)
Nail changes	233	94 (40.3)	61 (26.2)	78 (33.5)	237	72 (30.4)	143 (61.3)	22 (9.3)
Skin changes	230	101 (43.9)	54 (23.5)	75 (32.6)	238	91 (38.2)	128 (53.8)	19 (8.0)

ROM: range of movement.

motor symptom (27%), but when this was present only one patient reported a resolution. Vasomotor symptoms were again very common with more than 74% of patients reporting oedema, skin colour and temperature asymmetry and this being witnessed in ~60% of patients. Sweating was the least reported and witnessed sudomotor feature. Around one-third of patients reported trophic changes in each of the categories and around 30% of patients were seen to have these changes in each of the trophic categories upon recruitment.

Of the 160 patients in whom original hand dominance was recorded, 133 (83.1%) were right-handed. This is significantly lower than the average general population of 90% ( $p < 0.01$ ).<sup>14</sup> CRPS affected 50.2% of the cohort's right-side first and 48.1% had their arm affected first rather than their leg. In the 133 right hand-dominant patients, 26 (19.5%) had their left arm affected, 44 (33.1%) right arm, 35 (26.3%) left leg and 28 (21.1%) right leg. In the 27 left hand-dominant patients, 9 (33.3%) had their left arm affected, 5 (18.5%) right arm, 8 (29.6%) left leg and 5 (18.5%) right leg. Hence, it can be seen that there was no laterality preference, nor limb preference, dependent upon whether a patient was right or left hand dominant. This was confirmed by a Fisher's exact test investigating whether there was any association between hand dominance and first area affected ( $p = 0.302$ ).

CRPS was diagnosed in more than one limb for 30 (12.5%) out of 240 patients in this cohort. Only 5 (16.7%) out of 30 patients had diagonal contralateral spread (e.g. right arm and left leg), half of what was expected (33%,  $p = 0.054$ ). In all, 25 (83.3%) out of

30 patients with two limbs involved had had either spread to the same side of the body or same limb on contralateral side of CRPS.

The commonest trigger for CRPS was soft tissue injury (29.2%) followed by fracture (28.0%) and then surgery (23.7%). There was a high reported 'spontaneous' onset of CRPS (15.7%).

## Discussion

The inception of the CRPS-UK Registry following full ethical approval has been successful, and this Registry intends to continue to recruit patients with chronic disease who are being managed in centres experienced in this condition. As from mid-2013, the Registry has recruited 240 patients. These patients, with a mean age at symptoms onset of 43 years, had chronic disease (median duration 29 months), tended to be female (2.6:1) and were left-handed more than expected (21.8% versus 10% in the general population). Patients in the Registry often reported a delayed diagnosis, with the median time between symptom onset and diagnosis of 6 months. In all, 30 (12.5%) patients had multiple limb involvement and the spread affected the contralateral diagonal limb less frequently than expected, although not significantly so. Most patients reported ongoing pain and signs and symptoms consistent with their diagnosis despite the average symptom duration of nearly 2½ years.

When comparing the CRPS-UK Registry to the two community-based studies (Table 1), it is important to remember that these studies were designed to detect

incident cases whereas the average duration of symptoms in the CRPS-UK Registry population was nearly 3 years. Any potential differences between the community studies and the CRPS-UK Registry population may, therefore, relate to poor prognostic factors. There are several notable differences. The CRPS-UK Registry has a younger population with more male representation and more patients with multiple limb involvement. The CRPS-UK Registry also contains more patients with a spontaneous onset of their symptoms and a smaller proportion of patients with a fracture as a trigger. Finally, the CRPS-UK Registry has a greater proportion of patients with leg involvement (ratio of arm:leg 1:1). As expected, the Registry therefore differs from the community-based studies, and suggests that risk factors for poor prognosis may include males, younger age of onset, spontaneous onset and leg and multiple limb involvement.

In the published literature, 28 prognostic factors, both physical and psychological, identified from 12 studies are known to be associated with the outcome of patients with CRPS.<sup>15</sup> These include age less than 40 years, an initial presentation with a cold limb, the affected limb being a leg, more than one limb affected,<sup>16</sup> depression,<sup>17</sup> perceived lack of social support<sup>17</sup> and the use of anger as an emotional regulator.<sup>18</sup>

The self-reported delay between the symptom onset and diagnosis is long on average and highly variable in the CRPS-UK Registry. This did not vary significantly between centres, so that local factors are not suspected. This does support the accepted view that a delay in diagnosis predisposes a patient to enter secondary and tertiary care for the management of their CRPS. This is an area that is worthy of further study. Given that, community-based studies report that the symptoms of CRPS appear to self-limit in 70–80% of patients within the first year of onset, it would be important to make the correct diagnosis within 12 months to allow effective treatments and self-management to occur. Expert consensus states that early treatment is likely to improve long-term outcomes, although there is a paucity of data regarding this.<sup>19</sup> With the publication of the CRPS-UK Guidelines in 2011 (Royal College of Physicians), awareness and earlier diagnosis may be improved.<sup>11</sup> It would be interesting to see whether the delay to diagnosis changes over time in the CRPS-UK Registry over the next 5 years.

Patients with spontaneous onset of CRPS are recognised. This has previously been reported at the level of 5–10%.<sup>20</sup> Our data has a slightly higher prevalence of this group (15.7%). Perhaps this could be explained due to the chronic nature of this cohort of patients, suggesting a more severe phenotype. This is preliminary data and will need to be confirmed but perhaps suggests a different phenotype in this group of patients.

This is supported by De Mos et al.'s<sup>10</sup> data, suggesting that patients with fracture have a better outcome than patients who have CRPS unrelated to a fracture.

The aetiology of CRPS has remained elusive. Neurological hypotheses have been proposed.<sup>21</sup> In the propagation of CRPS to multiple limbs, contralateral diagonal spread would be expected to occur less commonly. This was suggested by the CRPS-UK Registry cohort and has previously been reported in a separate cohort.<sup>22</sup> Our data would therefore support a role for neural transmission in the spread of CRPS.

The CRPS-UK Registry is only one in a number of international registries. In the Netherlands, the TREND initiative has developed a network of interested clinicians and researchers with an active database of more than 1000 patients ([www.trendconsortium.nl](http://www.trendconsortium.nl)). In Switzerland, a specific CRPS Registry has been established to capture patients who develop CRPS following trauma or orthopaedic procedures.<sup>23</sup> In the United States, the Reflex Sympathetic Dystrophy Syndrome Association sponsors a self-registry web portal for patients with CRPS to register with the intention of following them up for 20 years ([www.rsds.org](http://www.rsds.org)). The CRPS-UK Registry will contribute to these differing approaches to recruiting patients with CRPS and will provide novel data, as well as allow the testing of hypotheses by recruiting patients into further studies. It is important to recognise the different patient populations that each Registry represents and this must be borne in mind when comparisons between datasets are made.

Despite the good recruitment into the CRPS-UK Registry, there will be concerns over the future validity of the data generated and the generalisability of the data. Patients enrolled into the CRPS-UK Registry have had the condition for nearly 3 years and are younger than expected. This is, therefore, a chronic cohort and not representative of all patients who are diagnosed with CRPS, as the majority improve within the first year of symptom onset.<sup>2,3</sup> Recruitment will need to be sustained over more than a decade to provide meaningful results.

In conclusion, the CRPS-UK Registry is actively recruiting well-characterised patients with CRPS to provide further information on the long-term outcome. The cohort demonstrates that most continue to have ongoing symptoms and signs of the condition. Analysis demonstrates a well-validated cohort of patients who are willing to engage in being followed up. We hope that this will stimulate further research efforts in the United Kingdom for advancing the understanding and management of this challenging condition, and for the Registry to be available for comparisons with other international registries in due course.

### Conflict of interest

Dr. Goebel declares having received research/travel support, consultancy or speaker honoraria for Pfizer, Axsome, Biotest, Baxter, CSL-Behring, Grifols, BPL. Prof. McCabe declares having received speaker fees from Pfizer and consultancy fees from GlaxoSmithKline. Dr Shenker declares lecture fees from Napp Educational Foundation; Pfizer; Menarini; Merck; and Roche amounting to less than £1000 per annum. The other authors declare no conflict of interest.

### Funding

Prof. McCabe is funded by a National Institute for Health Research Career Development Fellowship (CDF-2009-02-38). Yvette Hibberd and Lindsay Davies contributed to data collection, both of whom have received funds from the Bath Institute for Rheumatic Diseases.

### References

1. Harden RN, Bruehl SP, Stanton-Hicks M, et al. Proposed new diagnostic criteria for complex regional pain syndrome. *Pain Med* 2007; 8: 326–331.
2. De Mos M, de Bruijn AG, Huygen FJ, et al. The incidence of complex regional pain syndrome: a population-based study. *Pain* 2007; 129: 12–20.
3. Sandroni P, Benrud-Larson LM, McClelland RL, et al. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. *Pain* 2003; 103: 199–207.
4. Vaneker M, Wilder-Smith OHG, Schrombges P, et al. Impairments as measured by ISS do not greatly change between one and eight years after CRPS diagnosis. *Eur J Pain* 2006; 10: 639–644.
5. Kemler MA, de Vet HCW, Barendse GAM, et al. Effect of spinal cord stimulation for chronic complex regional pain syndrome type I: five-year final follow-up of patients in a randomized controlled trial. *J Neurosurg* 2008; 108: 292–298.
6. Zyluk A. The natural history of post-traumatic reflex sympathetic dystrophy. *J Hand Surg Br* 1998; 23: 20–23.
7. Geertzen JHB, Dijkstra PU, van Sonderen ELP, et al. Relationship between impairments, disability and handicap in reflex sympathetic dystrophy patients: a long-term follow-up study. *Clin Rehabil* 1998; 12: 402–412.
8. Galer BS, Henderson J, Perander J, et al. Course of symptoms and quality of life measurement in complex regional pain syndrome: a pilot survey. *J Pain Symptom Manage* 2000; 20(4): 286–292.
9. Field J, Warwick D, Bannister GC, et al. Long-term prognosis of displaced Colles' fracture: a 10-year prospective review. *Injury* 1992; 23: 529–532.
10. De Mos M, Huygen FJP, van der Hoeven-Borgman M, et al. Outcome of the complex regional pain syndrome. *Clin J Pain* 2009; 25: 590–597.
11. Turner-Stokes L and Goebel A. UK Guidelines on CRPS. *Clin Med* 2011; 11: 596–600.
12. Lamberg AL, Cronin-Fenton D and Olesen AB. Registration in the Danish Regional Nonmelanoma Skin Cancer Dermatology Database: completeness of registration and accuracy of key variables. *Clin Epidemiol* 2010; 2: 123–136.
13. Harboe KM, Anthonsen K and Bardram L. Validation of data and indicators in the Danish Cholecystectomy Database. *Int J Qual Health Care* 2009; 21: 160–168.
14. Peters M, Reimers S and Manning JT. Hand preference for writing and associations with selected demographic and behavioural variables in 255,100 subjects: the BBC internet study. *Brain Cogn* 2006; 62: 177–189.
15. Wertli M, Bachmann LM, Weiner SS, et al. Prognostic factors in Complex Regional Pain Syndrome 1: a systematic review. *J Rehabil Med* 2013; 45: 225–233.
16. Veldman PH and Goris RJ. Multiple reflex sympathetic dystrophy. *Pain* 1996; 64: 463–466.
17. Feldman SI, Downey G, Schaffer-Neitz R, et al. Pain, negative mood, and perceived social support in chronic pain patients: a daily diary study of people with reflex sympathetic dystrophy syndrome. *J Consult Clin Psychol* 1999; 67: 776–785.
18. Bruehl S, Chung OY and Burns JW. Differential effects of expressive anger regulation on chronic pain in CRPS and non-CRPS limb pain patients. *Pain* 2003; 104: 647–654.
19. Geertzen JHB, de Bruijn H, de Bruijn-Kofman AT, et al. Reflex sympathetic dystrophy: early treatment and psychological aspects. *Arch Phys Med Rehabil* 1994; 75: 442–446.
20. De Rooij AM, Perez RSGM, Huygen FJ, et al. Spontaneous onset of complex regional pain syndrome. *Eur J Pain* 2010; 14: 510–513.
21. Marinus J, Moseley GL, Birklein F, et al. Clinical features and pathophysiology of complex regional pain syndrome. *Lancet Neurol* 2011; 637–648.
22. van Rijn MA, Marinus J, Putter H, et al. Spreading of complex regional pain syndrome: not a random process. *J Neural Transm* 2011; 118: 1301–1309.
23. Brunner F, Bachmann LM, Weber U, et al. Complex Regional Pain Syndrome 1 – the Swiss cohort study. *BMC Musculoskel Dis* 2008; 9: 92.



## Appendix 1

### *Variable collected in the CRPS-UK Registry*

1. Date of birth
2. Hospital number
3. Address
4. GP
5. Screening date
6. Assessor
7. Diagnosis
8. Trigger
9. Original dominance
10. Current dominance
11. Area involved
12. Symptom of pain
13. Sign of allodynia
14. Sign of hyperalgesia
15. Symptoms of temperature asymmetry
16. Sign of temperature asymmetry
17. Symptom of colour asymmetry
18. Sign of colour asymmetry
19. Symptom of swelling
20. Sign of oedema
21. Symptom of sweating asymmetry
22. Sign of sweating asymmetry
23. Symptom of reduced range of movement
24. Sign of reduced range of movement
25. Symptom of weakness
26. Sign of weakness
27. Symptom of tremor
28. Sign of tremor
29. Symptom of muscle spasm
30. Sign of dystonia
31. Symptom of hair changes
32. Sign of hair changes
33. Symptom of nail changes
34. Sign of nail changes
35. Symptom of skin changes
36. Sign of skin changes
37. Research/Diagnostic criteria met